home / stock / acor / acor news


ACOR News and Press, Acorda Therapeutics Inc. From 02/14/19

Stock Information

Company Name: Acorda Therapeutics Inc.
Stock Symbol: ACOR
Market: NASDAQ
Website: acorda.com

Menu

ACOR ACOR Quote ACOR Short ACOR News ACOR Articles ACOR Message Board
Get ACOR Alerts

News, Short Squeeze, Breakout and More Instantly...

ACOR - Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript

Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella – Executive Director-Investor Relations Ron Cohen – Chief Executive Officer Conference Call Participants Cory Kasimov – JP M...

ACOR - Acorda Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Slides

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

ACOR - Acorda Q4 Ampyra sales down 62% on generic encroachment

Acorda Therapeutics (NASDAQ: ACOR ) Q4 results ($M): Revenues: 69.2 (-63.3); Ampyra sales: 64.2 (-61.6%) due to generic competition. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

ACOR - Acorda Appoints Peter S. Carbone Senior Vice President, Quality

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Company’s Leadership Team. In his role, Mr. C...

ACOR - Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific - New Research Emphasizes Economic Growth

NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Rexnord Corporation (NYSE:RXN), Carlisle Companies Incorporated (NYSE:...

ACOR - Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) o...

ACOR - New Hope For Acorda Therapeutics In 2019

Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,...

ACOR - Daily Insider Ratings Round Up 1/24/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

ACOR - Daily Insider Ratings Round Up 1/22/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

ACOR - Daily Insider Ratings Round Up 1/9/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Previous 10 Next 10